ExtaviPro® 30G – A solution to low adherence in Multiple Sclerosis (MS) treatment
The Owen Mumford Challenge
Multiple Sclerosis (MS) is a chronic debilitating inflammatory disease of the central nervous system and currently affects 2.5 million people worldwide. Patients often have to live with symptoms like blurred vision, cognitive impairment, and poor co-ordination. Presently there is no curative treatment; instead there are several disease-modifying therapies (DMTs) that aim to control the disease course, like preventing relapse, and slowing disease as well as disability progression.1
Due to MS’s chronic nature, people may live with the disease for several decades.2 One particular treatment (interferon beta-1b) has shown some impressive results by reducing all-cause mortality by 47% at 21 years in patients who received the treatment within their first two years of therapy, when compared with placebo.3 But despite the benefits of this promising form of MS therapy, it still faces one major issue – adherence.
Poor patient adherence to interferon beta-1b is often the result of adverse events relating to injectable therapies, like anxiety of injecting,1 injection site pain (ISP) and injection site reactions (ISRs). ISP and ISRs occur more often if patients inject into the skin rather than the muscle, and because interferon beta-1b is injected into the skin this can greatly affect how patients adhere to their treatment schedule. MS patients have to follow their treatment protocol to prevent relapse, and not adhering could be putting their health at risk.3